BeiGene
BGNE
#954
Rank
A$32.12 B
Marketcap
$293.64
Share price
0.49%
Change (1 day)
10.28%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Earnings for BeiGene (BGNE)

Earnings in 2024 (TTM): -A$1.3 Billion

According to BeiGene 's latest financial reports the company's current earnings are A$3.31 Billion. In 2023 the company made an earning of -A$1.93 Billion, an increase over its 2022 earnings that were of -A$2.85 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for BeiGene from 2015 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -A$1.3 Billion-32.38%
2023 -A$1.93 Billion-32.52%
2022 -A$2.85 Billion24.39%
2021 -A$2.29 Billion-13.21%
2020 -A$2.64 Billion72.69%
2019 -A$1.53 Billion36.01%
2018 -A$1.13 Billion616.83%
2017 -A$0.16 Billion-15.24%
2016 -A$0.19 Billion107.91%
2015 -A$88.83 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-A$28.87 Million-97.92%๐Ÿ‡บ๐Ÿ‡ธ USA
-A$0.19 Billion-86.49%๐Ÿ‡บ๐Ÿ‡ธ USA